Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches

•Use of SABR for central lung tumors has been increasing.•Central lung tumors can be subdivided into ‘moderately central’ and ‘ultracentral’.•Toxicity of SABR appears acceptable in ‘moderately central’ tumors.•A high toxicity is seen when ultracentral tumors are treated using SABR.•Conventional radiotherapy appears more appropriate in ultracentral tumors.